Artikkel

Making a living on super fatty acids

Daniel Haga Hasselstrøm, Trond Vidar Hansen
Daniel Haga Hasselstrøm (to the left) starts his own company after just graduating his Masters. Here posing with his tutor Trond Vidar Hansen. Photo: Gunhild Haugnes. Bruk bildet.

Making a living on super fatty acids

Fatty acids can be the answer in the struggle against many diseases ranging from Asthma to Alzheimer.

With 1 million kroner in start-up money from The Norwegian Research Council’s student initiative in the bag he is now able to get his new company on its feet.

A lack of control on body inflammations can lead to several different diseases; common diseases like asthma, Parkinson, Alzheimer and heart and vascular diseases.

In the future, so called oxygenated fatty acids can develop into an important remedy against these hazardous diseases.

– Extremely potent

– These fatty acids are so powerful that they contribute considerably in preventing inflammations in getting out of control, says Hasselstrøm.

Today however, these types of fatty acids don’t reach the production line. The reason is basically that very few have the expertise and the experience necessary.

The Research Group LIPCHEM at the School of Pharmacy at UiO has developed unique knowledge on the subject after working within this field of study for a number of years.

oxygenated fatty acids

oxygenated polyunsaturated fatty acids are created by omega-3 fatty acids in the body, like eicosapentaenoic acid and docosahexaenoic acid when you have an inflammatory condition, for example when injured or  experiencing an bacterial infection.

Fatty acids like these are extremely potent and can contribute in stopping an inflammatory condition.

With the new start-up company OXYPUFA, founder Daniel Haga Hasselstrøm aims to produce and sell these kinds of fatty acids to the pharmaceutical industry, who on their part can develop medicines that are effective based on these acids.

– The pharmaceutical industry doesn’t have to create the fatty acids and develop expensive expertise themselves. They save time, says Haga Hasselstrøm who completed his Master’s degree at the School of Pharmacy this spring semester.

In demand

And the demand is huge. The past few years Professor Trond Vidar Hansen at the School of Pharmacy has received plenty of interest from companies wishing to purchase the oxygenated fatty acids that his research group LIPCHEM have developed.

– Many of the oxidized fatty acids we have developed are worth their weight in gold. They are finished products already ready for sale.

Daniel Haga Hasselstrøm
New business founder Daniel Haga Hasselstrøm. Photo: Gunhild M. Haugnes/UiO.

– This provides the new company with a lucrative business opportunity and a clear advantage in the marketplace, Hansen adds.

Furthermore, the research group collaborates with the renowned professor Charles N. Serhan at Harvard Medical School concerning the chemistry, biochemistry and biology of oxidized fatty acids.

– This represents a paradigm shift within biomedicine and life sciences, Hansen proclaims.

Delivering the commodity

Hasselstrøm emphasizes that it is not OXYPUFA that is going to develop the medicine itself.

– We deliver the foundation or raw material to the pharmaceutical industry. It could take as much as 10-12 years before a finished medical product is marketed, he points out.

At the start the founder himself will own 52 percent of OXYPUFA. Additionally, Hansen and three other scientists Marius Aursnes, Jens Eivind Tungen and Anders Vik will be offered to own the rest of the company.

Hansen also strongly believes in Haga Hasselstøm as a businessman.

– He represents the new generation that combine expertise, involvement, ideas and a spirit of entrepreneurship. That Daniel has seen the huge commercial potential that this new paradigm represents, is a proof of his good thinking and creativity, he says.

Received a million in Funds

This spring the Government and the Norwegian Research Council arranged a business start-up competition through the initiative “FORNY StudENT”. 15 million kroner was set aside to sponsor the best student ideas and put them in motion.

Haga Hasselstrøm was one of the lucky students that could celebrate being chosen. He knows very well what he wants to do with the money.

«Forny student» initiative

The Norwegian Research Council hands out one million each to 15 different student start-up companies.

The new initiative “FORNY StudENT” aims to make the path into entrepreneurship easier than today for students.

53 master program students applied for money and 15 was singled out for grants.

– The money will go to establishing the business and follow up on the first customer requests. In addition, the funds will finance the actual manufacturing of the fatty acids: Purchasing chemicals, lab equipment, salaries and use of analytic equipment, he says.

He believes OXYPUFA will survive on these funds during the start-up period, but he can’t rule out the need for outside investors in the future. The company will also collaborate with the University of Oslo through their commercial initiative Inven2.

(Translated from Norwegian into English by Espen Haakstad)

Also read at Titan.uio.no:

– Like killing bacteria with a bulldozer

Modeling the brain as an electrochemial machine

Other articles in english

Contact information:

Daniel Haga Hasselstrøm

Professor Trond Vidar Hansen at the Department of Pharmaceutical Chemistry

Les også

artrose, kne

Håp for alle med slitasjeskader i ledd

Flere hundre tusen nordmenn sliter med slitasjeskader i leddene sine. Nå er det håp. Om noen år kan den smertefulle plagen kanskje behandles med stamceller og genterapi.

Dag O. Hessen og Nils Chr. Stenseth

Norsk-kinesisk forskersamarbeid for å redusere nitrogenutslipp

Kina står i dag for en tredel av verdens forbruk av nitrogenholdig kunstgjødsel, som også forårsaker alvorlig forurensning. Men nå vil myndighetene i Kina redusere utslippene til et bærekraftig nivå. UiO-forskerne Dag O. Hessen og Nils Chr. Stenseth har samarbeidet med kinesiske forskere og beregnet hvordan det målet kan oppnås.

Professor Kjetill S. Jakobsen ved Institutt for biovitenskap og CEES

DNA-kartlegging: Stadig raskere, billigere og viktigere

Mer enn 10 000 mennesker og mange milliarder kroner var involvert i kartleggingen av menneskets genom, som var noenlunde ferdig i 2003. I dag har teknologien kommet så mye lenger at fire-fem forskere ved kan lage en tilsvarende "utskrift" i løpet av et par uker. Men det er fortsatt svært krevende å tolke den, forteller professor Kjetill S. Jakobsen.